1Varma R, Rollason T, Gupta JK, Maher ER (2004) Endometriosis and the neoplastic process. Reproduction 127: 293-304.
2Wu MY, Ho HN (2003) The role of cytokines in endometriosis. Am J Reprod Immunol 49: 285-296.
3Steed H, Chapman W, Laframboise S (2004) Endometriosis-associated ovarian cancer: a clinicopathologic review. J Obstet Gynaecol Can 26: 709-715.
4Maeda D, Shih M (2013) Pathogenesis and the role of ARID1A mutation in endometriosis related ovarian neoplasms. Adv Anat Pathol 20: 45-52.
5Modesitt SC, Tortolero-Luna G, Robinson JB, Gershenson DM, Wolf JK (2002) Ovarian and extraovarian endometriosis-associated cancer. Obstet Gynecol 100: 788-795.
6Higashiura Y, Kajihara H, Shigetomi H, Kobayashi H (2012) Identification of multiple pathways involved in the malignant transformation of endometriosis. Oncol Lett 4: 3-9.
7McCluggage WG, Bryson C, Lamki H, Boyle DD (2000) Benign, borderline, and malignant endometrioid neoplasia arising in endometriosis in association with tamoxifen therapy. Int J Gynecol Pathol 19: 276-279.
8Cho KR, Shih IeM (2009) Ovarian cancer. Annu Rev Pathol 4: 287-313.
9Jones S, Wang TL, Shih le M, Mao TL, Nakayama, et al. (2010) Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 330: 228-231.
10Guan B, Wang TL, Shih leM (2011) ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res 71: 6718-6727.
11Wei JJ, William J, Bulun S (2011) Endometriosis and ovarian cancer: a review of clinical, pathologic, and molecular aspects. Int J Gynecol Pathol 30: 553-568.
12Bell KA, Kurman RJ (2000) A clinicopathologic analysis of atypical proliferative (borderline) tumors and well-differentiated endometrioid adenocarcinomas of the ovary. Am J Surg Pathol 24: 1465-1479.
13Zhao C, Wu LS, Barner R (2011) Pathogenesis of ovarian clear cell adenofibroma, atypical proliferative (borderline) tumor, and carcinoma: clinicopathologic features of tumors with endometriosis or adenofibromatous components support two related pathways of tumor development. J Cancer 2: 94-106.
14Mandai M, Matsumura N, Baba T, Yamaguchi K, Hamanishi J, et al. (2011) Ovarian clear cell carcinoma as a stress-responsive cancer: influence of the microenvironment on the carcinogenesis and cancer phenotype. Cancer Lett 310: 129-133.
15Kobayashi H, Yamada Y, Kanayama S, Furukawa N, Noguchi T, et al. (2009) The role of hepatocyte nuclear factor-1beta in the pathogenesis of clear cell carcinoma of the ovary. Int J Gynecol Cancer 19: 471-479.
16Kim KR, Choi J, Hwang JE, Baik YA, Shim JY, et al. (2010) Endocervical-like (Mullerian) mucinous borderline tumours of the ovary are frequently associated with the KRAS mutation. Histopathology 57: 587-596.
17Shappell HW, Riopel MA, Smith Sehdev AE, Ronnett BM, Kurman RJ (2002) Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas. Am J Surg Pathol 26: 1529-1541.
18Rambau PF, McIntyre JB, Taylor J, Lee S, Ogilvie T, et al. (2017) Morphologic reproducibility, genotyping, and immunohistochemical profiling do not support a category of seromucinous carcinoma of the ovary. Am J Surg Pathol 41: 685-695.
19Kurman RJ, Shih IeM (2008) Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol 27: 151-160.
20Pavone ME, Lyttle BM (2015) Endometriosis and ovarian cancer: links, risks, and challenges faced. Int J Womens Health 7: 663-672.
21Fukunaga M, Nomura K, Ishikawa E, Ushiqome S (1997) Ovarian atypical endometriosis: its close association with malignant epithelial tumours. Histopathology 30: 249-255.
22Stern RC, Dash R, Bentley RC, Snyder MJ, Haney AF, et al. (2001) Malignancy in endometriosis: frequency and comparison of ovarian and extraovarian types. Int J Gynecol Pathol 20: 133-139.
23Asch E, Levine D (2007) Variations in appearance of endometriomas. J Ultrasound Med 26: 993-1002
24Lall Seal S, Kamilya G, Mukherji J, De A, Ghosh D, et al. (2011) Aromatase inhibitors in recurrent ovarian endometriomas: report of five cases with literature review. Fertil Steril 95: 291.e15-e18.
25Laschke MW, Menger MD (2012) Anti-angiogenic treatment strategies for the therapy of endometriosis. Hum Reprod Update18: 682-702.
26Lu D, Song H, Li Y, Clarke J, Shi G (2012) Pentoxifylline for endometriosis. Cochrane Database Syst Rev 1: CD007677.
27Ngo C, Nicco C, Leconte M, Chéreau C, Weill B, et al. (2010) Antiproliferative effects of anastrozole, methotrexate, and 5-fluorouracil on endometriosis in vitro and in vivo. Fertil Steril 94: 1632-8.e1.
28Koninckx PR, Craessaerts M, Timmerman D, Cornillie F, Kennedy S (2008) Anti-TNF-alpha treatment for deep endometriosis-associated pain: a randomized placebo-controlled trial. Hum Reprod 23: 2017-2023.